Dr. Reddy’s Laboratories has completed a definitive transaction with Johnson & Johnson to acquire Stugeron Forte and Stugeron Plus across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets.Stugeron Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. With Stugeron already holding first position in the Cinnarizine represented pharmaceutical market (RPM) and ranked second in the anti-vertigo extended represented pharmaceutical market (eR ...

The transaction covers 18 markets across APAC and EMEA, with India and Vietnam identified as focus geographies. Stugeron, which contains the antihistamine Cinnarizine, is prescribed for vestibular disorders and vertigo.In India, the brand leads the Cinnarizine-represented pharmaceutical market (RPM) and ranks second in the broader anti-vertigo represented pharmaceutical market (eRPM). The deal will help Dr. Reddy’s strengthen its Central Nervous System (CNS) portfolio and expand in the anti-vertigo space.“ ...